WOBURN, Mass. , June 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that Quell technology will be used in a double-blinded, randomized, sham-controlled trial to determine whether transcutaneous electrical nerve stimulation (TENS) is an effective, acceptable and
WOBURN, Mass. , June 09, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that top-line results from a randomized controlled trial of Quell in patients with fibromyalgia will be presented at two upcoming pain medicine conferences.
WOBURN, Mass. , April 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2021 . The Company is a leader in proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological
WOBURN, Mass. , April 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 first quarter financial results before the opening of the market on April 22, 2021 . The Company will host a conference call at 8:00 a.m., Eastern Time on April 22,
WOBURN, Mass. , Jan. 28, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and year ended December 31, 2020 . The Company is focused on the development and global commercialization of non-invasive medical devices for the
WOBURN, Mass. , Jan. 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2020 fourth quarter and full year financial results before the opening of the market on January 28, 2021 . The Company will host a conference call at 8:00 a.m., Eastern Time
WOBURN, Mass. , Oct. 22, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2020 . The Company is a leading developer of neurostimulation-based medical devices that are used to diagnose and treat chronic
WOBURN, Mass. , Oct. 15, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 third quarter financial results before the opening of the market on October 22, 2020 . The Company will host a conference call at 8:00 a.m., Eastern Time on October 22,
WOBURN, Mass. , Sept. 22, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) today reported the launch of the Quell Watch App , now available for download from the Apple App store. The Quell Watch app gives a Quell user the ability to control and monitor their pain relief from their Apple
WOBURN, Mass. , Sept. 21, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office will issue on September 22, 2020 U.S. Patent No. 10,780,269 titled “Apparatus and Method for Relieving Pain Using Transcutaneous Electrical Nerve
